Case Study

The Benefits Of Late-Stage Customization For Orphan Drug Manufacturing

Source: Almac Group
The Benefits Of Late-Stage Customization For Orphan Drug Manufacturing

It is estimated that 25-30 million people are impacted by rare diseases which require orphan drug treatment across Europe. These are patients with conditions which impact one or fewer people per 2000, such as Crohn’s disease or neurofibromatosis.

Orphan drugs, synthetic pharmaceuticals intended to treat very rare diseases, are high cost/low demand products. This means they aren’t developed by the pharmaceutical industry on a very large scale.

Almac explains how, through the use of the Hapa BlisterJet printer, they are able to maximize the stock flexibility of their clients’ valuable orphan drug products, meaning they can distribute product more efficiently between different European countries.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: